-
Subject Areas on Research
-
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.
-
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
-
Advances in the treatment of invasive neonatal candidiasis.
-
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.
-
Anidulafungin: a new echinocandin for the treatment of fungal infections.
-
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.
-
Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit.
-
Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.
-
Antifungal agents in children.
-
Antifungal resistance: the clinical front.
-
Antifungal serum concentration monitoring: an update.
-
Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.
-
Antifungal treatment in pediatric patients.
-
Breakthrough invasive candidiasis in patients on micafungin.
-
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
-
Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis.
-
Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach.
-
Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus.
-
Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae.
-
Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides.
-
Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus.
-
Candida infective endocarditis: an observational cohort study with a focus on therapy.
-
Caspofungin exposure alters the core septin AspB interactome of Aspergillus fumigatus.
-
Caspofungin for invasive candidiasis at a tertiary care medical center.
-
Caspofungin for the treatment of azole resistant candidemia in a premature infant.
-
Caspofungin versus amphotericin B for invasive candidiasis.
-
Caspofungin-Mediated Growth Inhibition and Paradoxical Growth in Aspergillus fumigatus Involve Fungicidal Hyphal Tip Lysis Coupled with Regenerative Intrahyphal Growth and Dynamic Changes in β-1,3-Glucan Synthase Localization.
-
Caspofungin: first approved agent in a new class of antifungals.
-
Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy.
-
Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.
-
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
-
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.
-
Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
-
Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.
-
Comparison of caspofungin and amphotericin B for invasive candidiasis.
-
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
-
Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures.
-
Current options in antifungal pharmacotherapy.
-
Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus.
-
Echinocandin pharmacodynamics: review and clinical implications.
-
Echinocandins for the nursery: an update.
-
Echinocandins: a wealth of choice--how clinically different are they?
-
Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.
-
Echinocandins: role in antifungal therapy, 2005.
-
Emerging echinocandins for treatment of invasive fungal infections.
-
Engineering of New Pneumocandin Side-Chain Analogues from Glarea lozoyensis by Mutasynthesis and Evaluation of Their Antifungal Activity.
-
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
-
Evaluation of in vitro antifungal activity of LY121019.
-
Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
-
Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients.
-
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.
-
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
-
Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
-
Heat shock protein 90 is required for conidiation and cell wall integrity in Aspergillus fumigatus.
-
Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.
-
Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus.
-
Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin.
-
Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus.
-
In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains.
-
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.
-
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
-
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.
-
In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.
-
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
-
Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles.
-
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
-
Management of invasive mycoses in hematology patients: current approaches.
-
Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis.
-
Micafungin: the US perspective.
-
Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment.
-
Nebulizer delivery of micafungin aerosols.
-
New Spins on Old Drugs: Enhancing Activity of Antifungals.
-
New facets of antifungal therapy.
-
Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.
-
Pediatric antifungal agents.
-
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
-
Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
-
Pharmacokinetics of an elevated dosage of micafungin in premature neonates.
-
Pharmacokinetics of antifungal agents in children.
-
Pharmacological resolution of a multiloculated Candida spp. liver abscess in a preterm neonate.
-
Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
-
Population pharmacokinetics of micafungin in neonates and young infants.
-
Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.
-
Potential Microbiological Effects of Higher Dosing of Echinocandins.
-
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
-
Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.
-
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.
-
Role of echinocandins in the management of fungal infections in neonates.
-
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
-
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.
-
Safety and pharmacokinetics of repeat-dose micafungin in young infants.
-
Safety experience with caspofungin in pediatric patients.
-
Safety of micafungin in infants: insights into optimal dosing.
-
Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs.
-
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide.
-
Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.
-
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
-
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
-
The Aspergillus fumigatus P-type Golgi apparatus Ca2+/Mn2+ ATPase PmrA is involved in cation homeostasis and cell wall integrity but is not essential for pathogenesis.
-
The chitin synthase genes chsA and chsC are not required for cell wall stress responses in the human pathogen Aspergillus fumigatus.
-
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.
-
Timely Endocytosis of Cytokinetic Enzymes Prevents Premature Spindle Breakage during Mitotic Exit.
-
Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus.
-
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin.
-
Treatment of experimental disseminated candidiasis with cilofungin.
-
Treatment options for invasive fungal infections.
-
Use of newer antifungal therapies in clinical practice: what do the data tell us?
-
β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.
-
Keywords of People